A. Baras

Common genetic variants identify targets for COVID-19 and individuals at 1 high risk of severe disease 2

A. Girshick, D. Rader, C. O'Dushlaine, 2021 .

Recombinant BCG overexpressing STING agonist elicits trained immunity and improved antitumor efficacy in non-muscle invasive bladder cancer

Liang Zhao, W. Bishai, D. Pardoll, 2020 .

Drug development risk and the cost of capital

K. Schulman, A. Baras, A. Baras, 2012, Nature Reviews Drug Discovery.

Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of New York City Metro Blood Donors using Multiple SARS-CoV-2 Serological Assays: Implications for Controlling the Epidemic and Reopening.

Daniel J. Nesbitt, C. Hillyer, C. Kyratsous, 2020, medRxiv.

LBA50 Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816

J. Taube, P. Illei, E. Gabrielson, 2022, Annals of Oncology.

YolOOD: Utilizing Object Detection Concepts for Out-of-Distribution Detection

A. Shabtai, Y. Elovici, Satoru Koda, 2022, ArXiv.